DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the REMUS PHARMACEUTICALS L (REMUS) share price today?

REMUS PHARMACEUTICALS L (REMUS) is trading at ₹734.1 on the NSE, down 0.45% on the day. Source: DocStoX.

What is the PE ratio of REMUS PHARMACEUTICALS L?

REMUS PHARMACEUTICALS L has a price-to-earnings (PE) ratio of 23.4 in the Healthcare sector.

What is the market capitalisation of REMUS PHARMACEUTICALS L?

REMUS PHARMACEUTICALS L has a market capitalisation of approximately ₹0 crore.

REMUS PHARMACEUTICALS L

REMUS·NSE·Healthcare

₹734.10▼ -3.30 (-0.45%)

Healthcare · Pharmaceuticals

Revenue compounding 167% a year

Day₹720.00

₹740.00

52W₹580

₹99437%

Open

₹738.00

High

₹740.00

Low

₹720.00

Prev Close

₹737.40

Volume

3.3K

VWAP

₹733.37

Snapshot

Key fundamentals

Market Cap

₹0 Cr

P/E Ratio

23.39Fair

P/B Ratio

2.51

EPS

₹31.39

Book Value

₹298.00

ROE

12.20%Average

ROCE

17.00%Decent

Dividend Yield

0.07%

Debt / Equity

0.08Low

Face Value

₹10.00

52W High

₹993.95

52W Low

₹580.00

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatHigh uncertainty

Fair value estimate

₹335

▼ 54.3%downside

Trading at ₹734 — 54% above our estimate

BearFair valueBull

₹285₹335₹459

/100

Business quality — Solid

Growth 100Profitability 27Efficiency 23Valuation 81

Plain English

Our view

Revenue compounding 167% a year
Virtually debt-free balance sheet
Fundamental red flags (Piotroski 2/9)

Strengths

Virtually debt-free balance sheet
Revenue compounding 167% over 3 years
Profit growing 76% a year
Promoters hold a controlling stake

Risks

Fundamental red flags (Piotroski 2/9)

How we got there

Fair value methods

Residual income

12% ROE fading to 12% over ~3 yrs, on ₹298 book

₹301

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹459

Analyst target

No analyst coverage

—

Blended fair value₹335

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Revenue compounding 167% over 3 years
Profit growing 76% a year
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 2/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

23.4Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

12.2%Average

Above 15% is considered healthy for Indian equities

ROCE

17.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.08Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

—

P/B

2.51

EPS

₹31.39

Div Yield

0.07%

What changed

Recent changes

Foreign investors+5.3% stake last quarter
Domestic institutions+0.8% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 23.4×

Growth

Strong

+167% rev CAGR

Profitability

Healthy

12.2% ROE

Financial health

Rock solid

D/E 0.08

Momentum

N/A

No technicals

Today

Trading activity

Delivery %54.5%

Turnover₹24.20L Cr

Trades31

VWAP₹733.37

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+166.7%

+115.4%

10Y

—

Profit

+75.6%

+113.8%

10Y

—

EPS

—

10Y

—

Profile

Pros

Company is almost debt free.
Debtor days have improved from 107 to 59.8 days.

Watch-outs

Cons

Company has a low return on equity of 13.0% over last 3 years.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors bought 5.28 pts; domestic institutions added 0.83 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

71%

Promoter

Promoters

71.0%+0.04

Public

18.5%-0.28

FII / FPI

5.3%+5.28

DII

0.8%+0.83

Others

4.4%

Total shareholders

2,009-23 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter70.95%

FII5.28%

DII0.83%

Public18.50%

Others4.44%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 2015, Remus Pharma Ltd is in the business of trading and export of API and Finished Formulations and in Technical consultancy services[1]